Audit 365818

FY End
2024-12-31
Total Expended
$1.03M
Findings
0
Programs
2
Organization: Naprogenix, Inc. (KY)
Year: 2024 Accepted: 2025-09-08

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.273 Alcohol Research Programs $896,721 Yes 0
93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders $133,434 Yes 0

Contacts

Name Title Type
N1NBJ43SQGX7 Cindy Burklow Auditee
8592571127 Megan Crane Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: Expenditures reported on the Schedule are reported in conformity with accounting principles generally accepted in the United States of America (GAAP) basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. award activity of Naprogenix, Inc. (the Company) under programs of the federal government for the year ended December 31, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Regulations, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Company, it is not intended to and does not present the financial position, changes in stockholders' deficit, or cash flows of the Company.